JAVMA study details atypical radiographic changes with Librela

A JAVMA study is putting a finer point on an emerging Librela safety question: atypical radiographic changes in a small number of dogs treated with bedinvetmab. The study describes a pattern now being referred to as abnormal periarticular bone remodeling, or APBR, based on adverse-event reports with enough medical detail and imaging to allow case review. In outside commentary, Zoetis said 186 dogs meeting the study criteria were identified from its global pharmacovigilance database during a period in which about 34 million doses were dispensed. (dvm360.com)

The backdrop is a broader safety debate around anti-NGF therapy in dogs. FDA approved Librela on May 5, 2023, for control of pain associated with osteoarthritis in dogs. Since then, post-market surveillance has drawn increasing scrutiny. In a Dear Veterinarian letter, FDA said it had evaluated reported adverse events in dogs treated with Librela, including neurologic signs, urinary incontinence, polyuria, and polydipsia, with some reports ending in death or euthanasia. FDA also noted that wider real-world use can uncover adverse events not seen before approval. (fda.gov)

The current U.S. prescribing information already reflects some of that caution. The label says the safe use of anti-NGF monoclonal antibodies with concurrent NSAIDs has not been established in dogs, notes that rapidly progressive osteoarthritis was reported in a small number of human patients receiving anti-NGF therapy, and states that long-term effects beyond nine months have not been evaluated in dogs. It also instructs veterinarians to review the client information sheet before each injection and discuss serious adverse reactions that can occur, including reactions that may result in death or euthanasia. (animaldrugsatfda.fda.gov)

What’s new in the JAVMA paper is the effort to characterize a specific imaging phenotype rather than a general adverse-event signal. According to the study summary and follow-up interview, the authors reviewed musculoskeletal adverse-event reports from the Zoetis Global Pharmacovigilance database and focused on cases that included sufficient clinical information plus radiographs or radiology reports. In the dvm360 interview, Zoetis’ Mike Goldstein emphasized that the study does not establish causality and said it remains unclear whether Librela is driving the process, whether some dogs are predisposed, or whether similar changes may also occur in dogs not treated with the drug. (unboundmedicine.com)

That caution is important, but regulators are already reacting to the broader signal. In the U.K., the Veterinary Medicines Directorate announced an SPC update for Librela that added a precaution advising clinicians to consider additional diagnostics and possible discontinuation on a case-by-case basis when a dog develops new or increased joint swelling or joint pain after treatment. In the U.S., FDA says it is posting Librela adverse-event information on a rolling basis and may work with the sponsor on labeling updates, post-approval studies, or additional reporting if warranted, though CVM does not currently have authority to mandate safety-related labeling changes. (gov.uk)

Why it matters: For veterinary professionals, this report reinforces that Librela prescribing now sits in a more surveillance-heavy environment than it did at launch. The practical takeaway isn’t necessarily to avoid the drug, but to tighten diagnostic discipline around osteoarthritis, document baseline orthopedic and neurologic status, and reassess quickly if a dog develops new pain, swelling, gait change, or function loss after injection. It also strengthens the case for follow-up radiography in dogs with changing musculoskeletal signs, especially when the clinical course doesn’t fit routine OA progression. Expert commentary tied to the study also underscored the need to confirm that a dog’s pain is truly OA, rather than neurologic disease or another pain source that could complicate treatment decisions. (dvm360.com)

The pharmacovigilance angle matters, too. Because this analysis came from post-market reports, underreporting, incomplete records, and selection bias are all possible limitations. At the same time, those same databases are often where rare but clinically meaningful safety patterns first emerge. FDA specifically asks veterinarians to include full medical history, number of prior Librela doses, and vial lot number when reporting cases, details that could become especially important if future analyses try to sort out timing, dose exposure, comorbidities, or concomitant medications. (fda.gov)

What to watch: The next key developments are likely to be whether APBR becomes more formally defined in the literature, whether U.S. labeling evolves further, and whether prospective or case-control work can identify risk factors, including any role for concurrent medications, preexisting orthopedic disease, or case selection patterns. (dvm360.com)